SELLAS Life Sciences (SLS) Common Equity (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Common Equity for 9 consecutive years, with $15.9 million as the latest value for Q3 2024.
- On a quarterly basis, Common Equity rose 515.26% to $15.9 million in Q3 2024 year-over-year; TTM through Sep 2024 was $15.9 million, a 515.26% increase, with the full-year FY2023 number at -$8.0 million, down 264.42% from a year prior.
- Common Equity was $15.9 million for Q3 2024 at SELLAS Life Sciences, up from $2.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $33.4 million in Q2 2021 to a low of -$8.0 million in Q4 2023.
- A 5-year average of $12.2 million and a median of $9.7 million in 2024 define the central range for Common Equity.
- Peak YoY movement for Common Equity: soared 783.29% in 2021, then plummeted 264.42% in 2023.
- SELLAS Life Sciences' Common Equity stood at $28.0 million in 2020, then fell by 27.23% to $20.3 million in 2021, then crashed by 76.16% to $4.9 million in 2022, then tumbled by 264.42% to -$8.0 million in 2023, then soared by 299.25% to $15.9 million in 2024.
- Per Business Quant, the three most recent readings for SLS's Common Equity are $15.9 million (Q3 2024), $2.9 million (Q2 2024), and $9.7 million (Q1 2024).